Leukemia stem cells (LSCs) are thought to drive the genesis of acute myeloid leukemia (AML) as well as relapse following chemotherapy, and AMPK (AMP-activated protein kinase)/FIS1 (Fission 1)-mediated mitophagy is required for self-renewal of human AML stem cells; therefore, inhibition of mitophagy might be a potential target for killing AML and LSCs [43]. Here, FIS1 is linked to acute myeloid leukemia.